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Abstract
The basic pathophysiology of epilepsy is still not fully understood. Epidemiological evidence
for epilepsy seems to suggest that it may not only be the propensity for seizures to occur. The
high prevalence of comorbidity and the finding that premature mortality is still increased in
those who are in long term remission, suggest that there is a systemic component to the
condition. This systemic component is an additional shared risk factor that can explain an
important proportion of the comorbidities of epilepsy as well as how an individual with
inactive epilepsy remains at an elevated risk of premature mortality. This systemic
component can be viewed from the perspective of a number of fundamental
pathophysiological processes: inflammation, oxidative stress, glycation and methylation
capacity. These processes are associated with all-cause mortality and there is also a growing
understanding of their impact on seizure processes. We propose that epilepsy be considered
as the sum of seizures and comorbidities caused by systemic dysfunction, and that the
comprehensive management of epilepsy should also include the management of the systemic
dysfunction.
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1. Introduction
Despite recent progress, the basic pathophysiology of ictogenesis and epileptogenesis is still
not fully understood [1-3]. In parallel, a number of observations suggest that epilepsy may
not be just a neurological condition - it is not just the propensity to have unprovoked seizures.
It appears to be more complex and there is a growing appreciation that it is important to
understand fully all the factors that are at play in people with epilepsy to allow the clinician
to manage the individual better. We examine observations that suggest epilepsy is not just a
neurological condition and that there is also a systemic component. We propose a schema for
the basic elements affecting the propensity for seizures to occur. What we propose, is a
significant shift in the way we consider epilepsy and, clearly, in the next steps, these concepts
require further investigation and verification.
2. Epilepsy is not just a neurological condition
2.1 High prevalence of comorbidity
Studies have consistently shown that numerous psychiatric and somatic conditions are more
prevalent in people with epilepsy than in those without. These comorbid associations have
been summarised recently [4]. The most important associations include structural and
functional diseases of the central nervous system such as stroke, dementia, and migraine but
non-neurological disorders are also increased. For instance, heart disease, hypertension,
chronic obstructive pulmonary disease, and neoplasm are more likely to occur in people with
epilepsy than in the general population [4]. A cross-sectional analysis of Canadian data
derived from almost 180,000 people surveyed between 1998 and 2001 showed that the
prevalence of digestive tract ulcers was at least 2.5 times greater in individuals with epilepsy
than in those without [5]. In the same study, gastrointestinal disorders (i.e. Crohn’s disease
and colitis) were 2.0 to 3.3 times more prevalent [5]. In an UK study of 1,041,643
individuals surveyed between 1995 and 1998, dementia was 5 to 25 times more likely
(depending on age) in people with epilepsy while gastrointestinal haemorrhage was overall
2.6 to 4 times as likely as well, along with congenital cardiac abnormalities which were
almost 9 times more likely [6].
Psychiatric comorbidities are common amongst people with epilepsy. The most frequent are
depression, anxiety and psychosis but schizophrenia has also been reported [4]. In the UK,
depression and anxiety has been reported to be almost twice as common in people with
epilepsy [6]. Similar findings have also been seen in Canada and the USA [7, 8]. A recent
systematic review reported that 6% of individuals with epilepsy suffer from comorbid
psychosis [9].
2.2 Premature mortality is still increased in those who are seizure free
Multiple studies have shown an increased risk of premature death in people with epilepsy as
compared with the general population. This has been summarised in a recent systematic
review prepared by the Mortality Task Force of the International League Against Epilepsy
[10]. Sudden unexpected death in epilepsy and status epilepticus are important causes of
epilepsy-related death but these generally account for fewer than 5% of deaths [11]. The
majority of underlying causes of death are related to somatic comorbidities. The most
frequent of these are non-cerebral neoplasm, cardiovascular and cerebrovascular disease [11].
Those with more severe epilepsy, convulsive rather than non-convulsive seizures, are at
greater risk of death [10]. Interestingly, however, among those who are seizure free, the risk
of premature mortality remains elevated. In a cohort of 695 individuals with a history of
epileptic seizures, even amongst those with only a single notified seizure, the risk of an early
death compared to the general population after almost 25 years of follow-up was increased by
between 49% (in those with an unknown cause) and 72% (in those with a putative aetiology),
controlling for differences in age, sex, and calendar year [12]
2.3 Evidence of systemic dysfunction
The increased prevalence of many comorbid conditions in people with epilepsy as well as the
persistent risk of increased premature mortality, seems to suggest that there is a non-
neurological component to epilepsy. There are multiple means by which comorbidities may
be related to epilepsy [4]. Amongst these, the shared risk factor model explains an important
proportion of the comorbidities of epilepsy as well as how an individual with inactive
epilepsy remains at an elevated risk of premature mortality. Shared risk factors may be
genetic (e.g. a SCN1a mutation resulting in epilepsy and cardiac arrhythmia) or structural
(e.g. traumatic brain injury resulting in epilepsy and cognitive deficits). We propose that
systemic dysfunction is an additional shared risk factor that may explain these observed
relationships.
2.4 Proposed ‘new’ delineation of Epilepsy
We propose that epilepsy is the sum of the seizures and comorbidities (see figure1). Seizures
are the result of the epileptogenicity of the epileptic focus/abnormal neuronal networks. The
epileptic focus has an inherent propensity to produce seizures but this propensity can be
aggravated by systemic dysfunction and reduced by antiepileptic drugs. As well as its effects
on epileptogenicity, the systemic dysfunction is also the basis for the comorbidities.
3. The non-neurological components of seizure disorder
Human physiology is complex and not fully understood particularly how most ill health
develops. Our prevailing medical model seeks specific causes for specific illnesses, but there
is a growing appreciation that there may be fundamental pathological processes underlying
most illnesses. Hence, some diseases may have the same underlying pathophysiological
processes and individuals manifest different illnesses due to genetic and constitutional
differences. From this perspective, the development of ill health or systemic dysfunction can
be viewed from several different fundamental processes including genetic [13] and epigenetic
causes [14]; mitochondrial efficiency [15, 16]; pathophysiological biochemical processes and
psychological stress. These processes are not fully distinct and there is substantial overlap
between them. Currently our knowledge base does not allow us to view the development of
ill health from the perspective of one overarching process. We will look at ill health from the
perspective of a growing understanding of a few fundamental pathophysiological biochemical
processes which appear to underlie ill health. We will also look briefly at mitochondrial
efficiency as the fundamental underlying process.
4. Pathophysiological biochemical processes as the basis for systemic dysfunction
Several pathophysiological biochemical processes that appear to be the basis for systemic
dysfunction have been identified. There are biomarkers for these processes and multiple large
scale epidemiological studies have shown that they are associated with all-cause mortality,
suggesting that these pathophysiological processes are essential and can lead to ill health and
mortality from all the major causes. The impact of these processes on ictogenesis and
epileptogenesis is less well defined but there is now a growing understanding of how they can
have an impact on epilepsy.
4.1 Chronic Systemic Inflammation
Chronic systemic inflammation is the result of the release of pro-inflammatory cytokines
from immune-related cells and the chronic activation of the innate immune system. It is a
physiological state which differs from acute inflammation where there are clinical symptoms
and signs. Serum C-reactive protein (CRP) is a commonly used biomarker for systemic
inflammation. There is clear evidence from many observational studies suggesting that CRP
levels are associated with cardiovascular and all-cause mortality. In a cohort study with
231,000 person-years of follow-up (median 14.3 years), CRP was positively associated with
risk of all-cause, cardiovascular and non-cancer non-cardiovascular mortality independent of
established risk factors. The hazard ratio of all-cause mortality (95 % CI) for those with CRP
in the >10 mg/l (versus <0.5 mg/l) was 1.87 (1.43-2.43) in men and 1.98 (1.50-2.63) in
women [17]. In a study involving over 70,000 subjects, cross-sectional analysis showed that
higher levels of CRP were associated with higher risk of psychological distress and
depression. The prospective analyses showed increasing CRP levels were also associated
with increasing risk for hospitalization with depression [18].
Systemic inflammation is thought to have an influence on the epileptogenic process. Any
brain injury, such as trauma, stroke, viral infection, febrile seizures and status epilepticus,
occurring at any time in life is a risk factor for developing epilepsy. After these events, brain
inflammation develops [19] suggesting that a pro-inflammatory state in the brain might play a
role in epileptogenesis [20]. This hypothesis is supported by two main lines of evidence: (1)
the upregulation of pro-inflammatory signals during epileptogenesis in the epileptic foci; (2)
pharmacological targeting of specific pro-inflammatory pathways after status epilepticus or in
kindling shows antiepileptogenic effects. The pro-inflammatory molecules’ effect on
increasing hyperexcitability probably involves rapid, non-transcriptional effects on glutamate
and GABA receptors, and transcriptional activation of genes involved in synaptic plasticity
[20]. The glia, especially the astrocytes and microglia, are thought to be intimately involved
in the inflammatory processes contributing to epileptogenesis [21].
4.2 Oxidative stress
Reactive oxygen species (ROS), including superoxide radical, hydrogen peroxide, hydroxyl
radical, and singlet oxygen, are generated during normal cellular metabolism [22, 23].
Physiological levels of ROS can be scavenged by enzymatic (e.g., superoxide dismutase,
catalase, glutathione peroxidase, glutathione reductase, and peroxiredoxins) and non-
enzymatic (e.g., vitamin C, vitamin E, and reduced form of glutathione) antioxidant defence
systems. Excessive ROS levels, however, due to increased ROS production, decreased
antioxidant defence ability lead to oxidative stress [24]. Excess ROS further reacts with nitric
oxide (NO) generating reactive nitrogen species such as peroxynitrite [25] [26].
Several studies undertaken in different clinical settings have shown an association between
increasing oxidative stress and mortality risk. As an example, a study of 21,031 participants
followed for a median of 5.8 years showed that those with a greater balance of antioxidant to
pro-oxidant lifestyle exposures had significantly lower all-cause, cancer and non-cancer
mortality [27].
The brain is particularly susceptible to oxidative stress as it uses higher amounts of oxygen
than other organs. The brain also contains high concentrations of polyunsaturated fatty acids
that are prone to lipid peroxidation, is rich in iron, which can catalyse hydroxyl radical
formation, and is low in catalase activity. Oxidative stress results in functional cellular
disruption and cellular damage and may cause subsequent cell death. Protein oxidation leads
to functional changes or deactivation of various enzymes [28]. Lipid peroxidation causes
membrane structure alterations that affect membrane fluidity and permeability and membrane
protein activity [29]. Oxidative stress is thought to be involved in the pathogenesis of some
neurological conditions and neurodegenerative disorders such as Alzheimer’s disease,
Parkinson’s and amyotrophic lateral sclerosis [30, 31]
Oxidative stress is one of the possible mechanisms in the pathogenesis of epilepsy, or it may
be one of the contributing mechanisms. Oxidative stress is thought to disrupt intracellular
calcium homeostasis gradually, leading to increased neuronal excitability, seizure
susceptibility and vulnerability to additional stress and neuronal cell loss. Mitochondrial
dysfunction is intimately linked to oxidative stress and they are thought to be important in
acute injuries and the development of acquired chronic epilepsy [32, 33].
4.3 Glycation
Glycation is the non-enzymatic covalent bonding of reducing sugars, such as fructose or
glucose, to proteins, lipids or nucleic acids, leading to the formation of advanced glycation
end-products (AGEs). This reaction is known as Maillard’s or browning reaction. Glycation
is part of normal metabolism, but excessive accumulation of AGEs in the tissues and in the
circulation leads to pathogenic effects. Glycation is accelerated by hyperglycaemia hence is a
particular problem for people with diabetes. The production of AGEs can result in cross-
linking of body proteins, leading to alteration of tissue structure and function. Pathogenic
effects are also mediated by AGEs’ ability to increase inflammation and oxidative stress [34].
AGEs are generated in the body and also ingested as part of our diet. Dietary AGEs (dAGEs)
are mainly produced by especially dry heat and high temperature cooking [35].
Glycation, through the generation of AGEs, is thought to be a causal factor in a whole gamut
of human illnesses. Indeed, many large scale epidemiological studies have demonstrated an
association between HbA1c, a marker of glycation, and all-cause mortality both in western
populations [36] [37, 38] and in a Japanese population [39].
There has been very little research on AGEs and epileptogenesis [40], but there is very good
evidence that AGEs increases systemic inflammation and oxidative stress [41], and thus have
an impact on seizures through these mechanisms.
4.4 Methylation capacity
Methylation is the biochemical process of transferring a methyl (-CH3) group to organic
molecules in the human body. Methylation is critical to nucleic acid synthesis, DNA
methylation (one of the main mechanisms for epigenetic changes), synthesizing
neurotransmitters, homocysteine metabolism, protein methylation, and liver detoxification.
Methylation capacity can be assessed by measuring a number of different molecules and
measuring homocysteine is one such measure. Inadequate methylation capacity as indicated
by raised homocysteine is seen in different diseases, including congenital birth defects, late
pregnancy complications, neurodegenerative and psychiatric diseases, osteoporosis and
cancer [42].
In a study including 1933 elderly subjects from the original Framingham Study cohort,
followed for a median of 10 years, the unadjusted relative risk for all-cause mortality was
2.18 (95% CI, 1.86-2.56) for the upper quartile of non-fasting total plasma homocysteine
levels vs the lower 3 quartiles. The study showed that elevated plasma total homocysteine
levels are independently associated with increased risk of all-cause mortality in the elderly
[43]. Studies have also shown associations between higher homocysteine levels and the
incidence of stroke. One study has shown that the observed increase in risk of stroke among
individuals homozygous for the MTHFR T allele is close to that predicted from the
differences in homocysteine concentration conferred by this variant. This was suggested to be
consistent with a causal relation between homocysteine concentration and stroke [44].
Plasma homocysteine levels are elevated in several neurological conditions including
epilepsy [45]. Homocysteine appears to potentiate seizures and cell loss in animal models of
epilepsy [46]. Homocysteine may contribute to ictogenesis through a variety of mechanisms
including its ability to inhibit GABA [47].
5. Mitochondrial efficiency as the basis of systemic dysfunction
Mitochondrial dysfunction has been implicated in the aging process and various human
disorders, such as cardiovascular and neurodegenerative diseases, cancer, migraine,
infertility, kidney and liver diseases and toxicity of drugs [48-50]. It is recognized that the
physiological role of mitochondria widely exceeds that of solely being the biochemical power
plant of our cells [48]. Mitochondrial efficiency is particularly important for neurological
functions as the brain constitutes 2% of the body mass yet accounts for 20% of the body’s
total oxygen consumption.
Recently, epilepsy has been reported in people who have mitochondrial respiratory chain
dysfunction, even when most of them do not have a specific phenotype as previously
described (e.g., myoclonic epilepsy in MERRF) nor due to specific gene mutation or
deletions [51, 52]
In a study of human brain specimens from 57 people with temporal lobe epilepsy, and two
control subjects, specific deficiency of complex 1 of the mitochondrial respiratory chain was
demonstrated in the hippocampal CA3 region in those with hippocampal foci and in the
parahippocampus in those with parahippocampal foci. This suggests that mitochondrial
dysfunction at the epileptic focus may be a mechanism contributing to the altered neuronal
excitability [53].
6. Implications
The evidence that epilepsy is associated with increased comorbidity is now irrefutable.
Together with the observation that even people with epilepsy in remission have an increased
risk of early mortality, this suggests that there is a systemic component contributing to their
ill health. These observations lead us to suggest that it may be helpful to consider epilepsy to
be the sum of seizures and comorbidities and that there is a systemic dysfunction that is the
primary contributor to the comorbidities. This systemic dysfunction can also aggravate
epileptogenicity and increase seizure occurrence.
The basis of this systemic dysfunction can be considered from the perspective of the
pathophysiological processes discussed above. We have provided the evidence as to how
these processes are associated with ill health and how they can modify epileptogenicity.
What might be the implication of accepting this view of epilepsy? If it is accepted that
systemic dysfunction can aggravate epileptogenicity and is the main contributor to the
comorbidities, then the comprehensive management of epilepsy should be focussed not only
on stopping seizures, but strategies to ameliorate the systemic dysfunction – reducing
systemic inflammation, glycation, oxidative stress and increasing methylation capacity – are
needed.
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Figure 1
Schema to show the role of Systemic dysfunction in producing Comorbidities
and increasing Epileptogenicity to produce Seizures.
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